Increasing apical aneurysm size in hypertrophic cardiomyopathy was associated with higher sudden cardiac death risk, from 0.2%/year in small to 8.2%/year in very large aneurysms (P<0.001).
Cohort (n=510)
Yes
Does apical aneurysm size predict sudden cardiac death and thromboembolic events in patients with hypertrophic cardiomyopathy?
In patients with hypertrophic cardiomyopathy and apical aneurysms, aneurysm size ≥10 mm is associated with a significantly higher risk of sudden cardiac death events and apical thrombi.
p-value: p=< 0.001
BACKGROUND: Apical aneurysms in hypertrophic cardiomyopathy (HCM) have been linked to sudden cardiac death (SCD) and a nidus for thromboembolism. Uncertainty remains regarding the level of risk and significance of aneurysm size. OBJECTIVES: The objective of the study was to determine the rate of SCD events and prevalence of apical thrombus or embolic events by size (maximum transverse dimension). METHODS: Apical aneurysms were identified in 510 patients from 10 centers, followed a median of 4.1 years for SCD events (SCD, appropriate implantable cardioverter defibrillator therapy, and resuscitated SCD) or development of apical thrombus/thromboembolism. Relationship between size and SCD events was analyzed using multivariable Cox proportional hazard models. RESULTS: In 510 HCM patients: 19% had small aneurysms (2%/year). Although embolic events were uncommon, increasing aneurysm size was associated with the prevalence of apical thrombi.
Rowin et al. (Wed,) conducted a cohort in Hypertrophic cardiomyopathy with apical aneurysms (n=510). Apical aneurysm size vs. Smaller aneurysm size was evaluated on SCD events (SCD, appropriate implantable cardioverter defibrillator therapy, and resuscitated SCD) (p=< 0.001). Increasing apical aneurysm size in hypertrophic cardiomyopathy was associated with higher sudden cardiac death risk, from 0.2%/year in small to 8.2%/year in very large aneurysms (P<0.001).